
19<sup>th</sup> Annual Conference of the British HIV Association (BHIVA)



# Dr C. Bryn Jones

#### Imperial College Healthcare NHS Trust, London

16-19 April 2013, Manchester Central Convention Complex



## CD4 point of care testing improves patient satisfaction and reduces recalls to clinic (Speedy4)

A Obi<sup>1</sup>, <u>CB Jones</u><sup>1,2</sup>, E Pizzo<sup>2</sup>, C Hart<sup>1</sup>, NE Mackie<sup>1,2</sup>, AC Bailey<sup>1</sup> <sup>1</sup>St Mary's Hospital, Imperial College Healthcare NHS Trust <sup>2</sup>Imperial College London







 Funding: This study was funded by NIHR-CLAHRC for North West London. PIMA testing was supported by Alere medical

 CBJ, NEM and ACB have received funding to attend conferences from a number of pharmaceutical companies







- CD4 testing remains an important prognostic marker
- The PIMA CD4 point of care (POCT) test has been validated in the UK<sup>1</sup>, with good levels of patient acceptability
- POCT CD4 testing has been shown to increase linkage into care in South Africa<sup>2</sup> and Mozambique<sup>3</sup>
- 1. Herbert et al . Sexually transmitted infections (2012); 88, 413-417 ir
- 2. Larson et al. JID (2012); 61; e13-e17
- 3. Jani et al. Lancet (2011); 378; 1572-79





- Overall aim of Speedy4 study
  - to assess the impact of a new CD4 point of care test (POCT) on patient pathways (recalls), patient satisfaction, efficiency and costs


- This presentation
  - to assess the impact of a new CD4 point of care test (POCT) on patient pathways, patient satisfaction, staff experience.
  - Poster P4 Title: Can we justify the use of a CD4
    Point of Care test in a time of austerity?

- Population: Newly diagnosed patients
  Not on ART (CD4>350)
- Prospective study in two phases
  - Phase 1: pathway mapping and collection of data on current pathway using venous sample for FACS CD4
  - Phase 2: implementation of PIMA CD4 and collection of data on new pathway
- Paper based participant questionnaires
  - Satisfaction, time and costs
- Staff proforma
  - Recalls, CD4 counts
- Staff questionnaire










## PIMA pathway Stable patients



**NHS Trust** 







- Recruited between 12/9/11 and 14/9/12
- 199 participants recruited

Phase	Stable	Newly diagnosed	Total
Phase 1 (lab)	85 (83.3)	17 (16.7)	102 (100)
Phase 2 (PIMA)	71 (73.2)	26 (26.8)	97 (100)
Total	156 (78.4)	43 (21.6)	199 (100)





## Study participants


Imperial College Healthcare **NHS** 

**NHS Trust** 


		N (%)
	Female	25 (12.6)
Sex	Male	174 (87.4)
	Total	199 (100)
	Not known/not answered	5 (2.5)
	Heterosexual	40 (20.1)
Risk Factor	MSM	154 (77.4)
	Total	199 (100)
		Median (IQR)
Age at test		38 (31-46)
	Newly diagnosed	384 (200-616)
Laboratory CD4 Count result -	Stable	520 (420-660)
median (IQR)	All participants	506 (400-652)
		N (%)
	Newly diagnosed	11 (26.2)
Requiring PCP prophylaxis	Stable	1 (0.8)
	All participants	12 (6.8)








### Patient reported – overall time in clinic





Difference in medians = 15 min




Difference in medians = 70 min

#### Recalls








## Staff satisfaction

#### Imperial College Healthcare

**NHS Trust** 





- The PIMA CD4 test
  - increased patient satisfaction (which was already high)
  - reduced the rate of recalls to clinic, particularly for new patients
  - Decreased the time patients spent in clinic for CD4 testing

## Conclusion

- PIMA CD4 testing streamlined pathways, particularly for newly diagnosed individuals
- Please also see poster P4 for economic evaluation





## Acknowledgements

- Study participants
- Study team
- NIHR CLAHRC for North West London
- Alere Medical







## 19th Annual Conference of the British HIV Association (BHIVA)

16-19 April 2013

**#BHIVA2013** 

Manchester Central Convention Complex